Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 41 (2) 336-342
Year:
2023
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-internal-user
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
12
Parents:
3254  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
Celgene (50803); GSK (50901 & 50904)  
Grants:
U10CA180821, U10CA180882, UG1CA233339, UG1CA233247, UG1CA233253, UG1CA233277, UG1CA233328, U10 CA180819 (SWOG)  
Corr. Author:
 
Authors:
                                                   
Networks:
CAPITAL, LAPS-IL057, LAPS-MN026, LAPS-MO011, LAPS-OH007, LAPS-WI020, NC012, NY018, NY167, PA121   
Study
Alliance-A151737
Multiple Studies, or Legacy Studies in Alliance Study:
Alliance-A051103, CALGB-50701, CALGB-50801, CALGB-50901, SWOG-S0016, SWOG-S0816
Phases:
N/A, 1, 2, 3
Keywords:
ORIGINAL REPORTS, Hematologic Malignancy